BeyondSpring reports Q2 2026 net loss of $1.8 million as cash falls to $6.5 million ahead of DUBLIN-4 launch

The post-ICI second-line NSCLC market has become one of oncology's more contested fields, with antibody-drug conjugate regimens pressing hard on older cytotoxic backbones. Against that backdrop, BeyondSpring Inc. (NASDAQ: BYSI) reported a net loss of $1.8 million for the quarter ended June 30, 2026, compared with $1.9 million in the same quarter of 2025, and disclosed that cash, cash equivalents, and short-term investments had fallen to $6.5 million from $12.6 million at year-end 2025.

Research and development expenses held flat at $1.0 million for the quarter. A $0.3 million uptick in drug manufacturing costs was offset by lower patent and personnel spending. General and administrative costs edged down to $0.8 million from $0.9 million, as legal and consulting fees tied to accounting advisory and business development came in lighter.

Clinical data and the DUBLIN-4 path

The numbers that matter operationally are clinical, not accounting. At ASCO 2026, BeyondSpring presented updated results from the investigator-initiated Phase 2 303 Study, which evaluated Plinabulin in combination with docetaxel and pembrolizumab in 47 patients with metastatic NSCLC whose disease had progressed after first-line immune checkpoint inhibitor therapy. As of a February 28, 2026 data cutoff, the combination showed a 12-month overall survival rate of 78.1% and a 24-month rate of 58.0%, with median overall survival not yet reached at a median follow-up of 28.8 months. Median progression-free survival was 7.0 months and the disease control rate was 79.5%.

At AACR 2026, preclinical data showed Plinabulin combined with the TROP-2-directed agent datopotamab deruxtecan and the HER2-directed agent trastuzumab deruxtecan improved complete tumor regression rates and survival, with or without PD-1/PD-L1 inhibition. The sector-wide read-through is clear: Plinabulin's claimed immune-activation mechanism positions it as a potential pairing agent for the ADC regimens that now define the treatment conversation in late-line NSCLC.

The company cites both data sets as scientific support for DUBLIN-4, a planned 442-patient, randomized, double-blind Phase 3 study in non-squamous, EGFR wild-type NSCLC patients who have progressed on PD-1/PD-L1 inhibitor therapies. The predecessor program, DUBLIN-3, was published in The Lancet Respiratory Medicine in 2024.

A leadership transition took effect July 1, 2026. Min Qiu assumed the chief executive role, Na Li was appointed Chief Financial Officer, and Dr. Jiangwen (Jen) Majeti became Vice Chairman. Dr. Lan Huang, Co-Founder and Chairman, now directs her executive attention primarily to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer.

Qiu, in remarks published with the August 14, 2026 results, described the company's near-term priorities as the regulatory, operational, and financing preparations needed to initiate DUBLIN-4. That last word is where the cash line concentrates attention: at the burn pace implied by the first half of 2026, the $6.5 million on hand is the number the DUBLIN-4 timeline has to clear first.